The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

proadifen     2-diethylaminoethyl 2,2-diphenylpentanoate

Synonyms: Proadifene, Proadifeno, Proadifenum, BCTB, Lopac-P-1061, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of proadifen


Psychiatry related information on proadifen


High impact information on proadifen

  • The effect of carbon tetrachloride (CCl4) on hepatocytes was substantially reduced by prior treatment with SKF 525A, an inhibitor of cytochrome P-450, and by exposure to the reducing reagent beta-mercaptoethanol [9].
  • The LTB4 omega-hydroxylase was inhibited significantly by carbon monoxide, ferricytochrome c, SKF-525A, and Triton X-100, but was not affected by alpha-naphthoflavone, azide, cyanide, catalase, and superoxide dismutase [10].
  • ACh-induced CD increases resistant to L-NAME and indomethacin were reduced after the administration of intracoronary quinacrine, an inhibitor of phospholipase A2, or proadifen, an inhibitor of cytochrome P-450 [11].
  • During proadifen-inhibited 42K efflux, exogenous K+ augmented overflow of 3HNE, indicating that proadifen relaxed the hypoxic artery primarily by inhibiting K+-dependent exocytosis of NE [12].
  • Because the inhibitory effects of PB on GJ intercellular communication are prevented by the nonspecific cytochrome P-450 inhibitor SKF-525A (J. E. Klauning, et al., Toxicol. Appl. Pharmacol., 102: 533-563, 1990), we investigated whether alterations in Cx32 are coincident with changes in the major PB-inducible cytochrome P-450, termed b/e or IIB1/2 [13].

Chemical compound and disease context of proadifen


Biological context of proadifen


Anatomical context of proadifen


Associations of proadifen with other chemical compounds


Gene context of proadifen

  • Carbon monoxide, SKF-525A, metyrapone, and benzylimidazole strongly inhibited N-demethylation and 4-hydroxylation, indicating the participation of P-450 monooxygenase in these reactions [34].
  • However, SKF-525A was ineffective against the effect of LPS alone on liver and blood GPx and CAT or on hepatic GSH and GRx, suggesting that these effects were not mediated by cytochrome P450 oxidative metabolism [35].
  • In contrast, SKF-525A weakly inhibited CYP1A2-dependent activities (46% inhibition at 1200 microM) and CYP2E1-dependent activities (65% inhibition at 1000 microM) [36].
  • Daily SKF-525A pretreatment at a dose of 30 mg/kg, i.p., for 7 days 1 hour prior to KET and COC in combination effectively reversed the effects of this combination on body weight, organ/bodyweight ratios, histopathology, and serum IgM and IL-10 concentrations without affecting leukocytic counts [37].
  • In contrast, we observed that CYP450 inhibitors such as SKF-525A, 17-octadecynoic acid, 1-aminobenzotriazole, and 6-(2-propargyloxyphenyl)hexanoic acid reduced 12(S)-HETE levels, 3T6 fibroblast growth, and DNA synthesis induced by FBS [38].

Analytical, diagnostic and therapeutic context of proadifen


  1. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. McMurtry, I.F., Davidson, A.B., Reeves, J.T., Grover, R.F. Circ. Res. (1976) [Pubmed]
  2. Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity. Smith, R.D., Kehrer, J.P. Cancer Res. (1991) [Pubmed]
  3. Protection and potentiation of 1-methyl-4-phenylpyridinium-induced toxicity by cytochrome P450 inhibitors and inducer may be due to the altered uptake of the toxin. Sriram, K., Pai, K.S., Ravindranath, V. J. Neurochem. (1995) [Pubmed]
  4. Alteration of delta 9-tetrahydrocannabinol-induced teratogenicity by stimulation and inhibition of its metabolism. Harbison, R.D., Mantilla-Plata, B., Lubin, D.J. J. Pharmacol. Exp. Ther. (1977) [Pubmed]
  5. The role of nephrectomy and proadifen in blood pressure homeostasis following an acute kinin-induced hypotension in normotensive rats. Holte, H.R., Berg, T. Br. J. Pharmacol. (1996) [Pubmed]
  6. Single-dose pharmacokinetics and anticonvulsant efficacy of primidone in mice. Leal, K.W., Rapport, R.L., Wilensky, A.J., Friel, P.N. Ann. Neurol. (1979) [Pubmed]
  7. Studies on the mechanism of interaction between methamphetamine and quinine in rats. Suzuki, T., Chiang, H.J., Yanaura, S., Yoshida, T., Kuroiwa, Y. J. Pharmacobio-dyn. (1986) [Pubmed]
  8. Effect of food deprivation, phenobarbital, and SKF-525A on teratogenicity induced by 2-sec-butyl-4,6-dinitrophenol (dinoseb) and on disposition of [14C]dinoseb in mice. Preache, M.M., Gibson, J.E. Journal of toxicology and environmental health. (1975) [Pubmed]
  9. Carbon tetrachloride at hepatotoxic levels blocks reversibly gap junctions between rat hepatocytes. Sáez, J.C., Bennett, M.V., Spray, D.C. Science (1987) [Pubmed]
  10. Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Partial purification and identification as a cytochrome P-450. Shak, S., Goldstein, I.M. J. Clin. Invest. (1985) [Pubmed]
  11. Nitric oxide-independent dilation of conductance coronary arteries to acetylcholine in conscious dogs. Ming, Z., Parent, R., Lavallée, M. Circ. Res. (1997) [Pubmed]
  12. Hypoxic contraction of isolated canine coronary artery. Mediation by potassium-dependent exocytosis of norepinephrine. Borda, L.J., Shuchleib, R., Henry, P.D. Circ. Res. (1980) [Pubmed]
  13. Colocalized alterations in connexin32 and cytochrome P450IIB1/2 by phenobarbital and related liver tumor promoters. Neveu, M.J., Babcock, K.L., Hertzberg, E.L., Paul, D.L., Nicholson, B.J., Pitot, H.C. Cancer Res. (1994) [Pubmed]
  14. Drug metabolite toxicity assessed in human lymphocytes with a purified, reconstituted cytochrome P-450 system. Leeder, J.S., Cannon, M., Nakhooda, A., Spielberg, S.P. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  15. Cocaethylene hepatotoxicity in mice. Roberts, S.M., Roth, L., Harbison, R.D., James, R.C. Biochem. Pharmacol. (1992) [Pubmed]
  16. Changes in glutathione and cellular energy as potential mechanisms of papaverine-induced hepatotoxicity in vitro. Davila, J.C., Davis, P.J., Acosta, D. Toxicol. Appl. Pharmacol. (1991) [Pubmed]
  17. Evidence for the possible formation of a toxic tyrosine metabolite by the liver microsomal drug metabolizing system. David, J.C. Naunyn Schmiedebergs Arch. Pharmacol. (1976) [Pubmed]
  18. Enhancement of DMNQ-induced hepatocyte toxicity by cytochrome P450 inhibition. Ishihara, Y., Shiba, D., Shimamoto, N. Toxicol. Appl. Pharmacol. (2006) [Pubmed]
  19. Inhibitory effect of free radicals derived from organic hydroperoxide on progesterone synthesis in human term placental mitochondria. Klimek, J., Woźniak, M., Szymańska, G., Zelewski, L. Free Radic. Biol. Med. (1998) [Pubmed]
  20. Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells. Smith, G.B., Castonguay, A., Donnelly, P.J., Reid, K.R., Petsikas, D., Massey, T.E. Carcinogenesis (1999) [Pubmed]
  21. Effect of a single oral dose of methanol, ethanol and propan-2-ol on the hepatic microsomal metabolism of foreign compounds in the rat. Powis, G. Biochem. J. (1975) [Pubmed]
  22. Subcellular localization and characterization of neuronal nitric oxide synthase. Hecker, M., Mülsch, A., Busse, R. J. Neurochem. (1994) [Pubmed]
  23. Defining the active site of cytochrome P-450: the crystal and molecular structure of an inhibitor, SKF-525A. Rossi, M., Markovitz, S., Callahan, T. Carcinogenesis (1987) [Pubmed]
  24. The identification and formation of 20-aldehyde leukotriene B4. Soberman, R.J., Sutyak, J.P., Okita, R.T., Wendelborn, D.F., Roberts, L.J., Austen, K.F. J. Biol. Chem. (1988) [Pubmed]
  25. Biotransformation of aflatoxin B1 in rabbit lung and liver microsomes. Daniels, J.M., Liu, L., Stewart, R.K., Massey, T.E. Carcinogenesis (1990) [Pubmed]
  26. 17 Alpha-ethinyl estradiol is more potent than estradiol in receptor interactions with isolated hepatic parenchymal cells. Dickson, R.B., Eisenfeld, A.J. Endocrinology (1981) [Pubmed]
  27. Acetylcholine-induced relaxation and hyperpolarization in small bovine adrenal cortical arteries: role of cytochrome P450 metabolites. Zhang, D.X., Gauthier, K.M., Campbell, W.B. Endocrinology (2004) [Pubmed]
  28. Characterization of vasoconstrictor responses in small bovine adrenal cortical arteries in vitro. Zhang, D.X., Gauthier, K.M., Campbell, W.B. Endocrinology (2004) [Pubmed]
  29. Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Goeptar, A.R., Groot, E.J., Scheerens, H., Commandeur, J.N., Vermeulen, N.P. Cancer Res. (1994) [Pubmed]
  30. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Haberle, D., Szökõ, E., Magyar, K. Current medicinal chemistry. (2002) [Pubmed]
  31. Metabolism of N-alkyl compounds during the biosynthesis of prostaglandins. N-Dealkylation during prostaglandin biosynthesis. Sivarajah, K., Lasker, J.M., Eling, T.E., Abou-Donia, M.B. Mol. Pharmacol. (1982) [Pubmed]
  32. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation. Jain, M., Kwon, C.H. J. Med. Chem. (2003) [Pubmed]
  33. Desensitization shortens the high-quantal-content endplate current time course in frog muscle with intact cholinesterase. Giniatullin, R.A., Talantova, M., Vyskocil, F. J. Physiol. (Lond.) (1997) [Pubmed]
  34. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Mani, C., Gelboin, H.V., Park, S.S., Pearce, R., Parkinson, A., Kupfer, D. Drug Metab. Dispos. (1993) [Pubmed]
  35. Inhibition of cocaine oxidative metabolism attenuates endotoxin potentiation of cocaine mediated hepatotoxicity. Labib, R., Turkall, R., Abdel-Rahman, M.S. Toxicology (2002) [Pubmed]
  36. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Emoto, C., Murase, S., Sawada, Y., Jones, B.C., Iwasaki, K. Drug Metab. Pharmacokinet. (2003) [Pubmed]
  37. Effect of ketamine on cocaine-induced immunotoxicity in rats. Rofael, H.Z., Turkall, R.M., Abdel-Rahman, M.S. International journal of toxicology. (2003) [Pubmed]
  38. Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth. Nieves, D., Moreno, J.J. J. Lipid Res. (2006) [Pubmed]
  39. Renal cytochrome P-450-dependent metabolism of arachidonic acid in cirrhotic rats. Sacerdoti, D., Escalante, B.A., Schwartzman, M.L., Abraham, N.G., Gatta, A., McGiff, J.C. J. Hepatol. (1991) [Pubmed]
  40. Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Lafranconi, W.M., Huxtable, R.J. Biochem. Pharmacol. (1984) [Pubmed]
  41. Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. Sato, Y., Shibanoki, S., Sugahara, M., Ishikawa, K. Br. J. Pharmacol. (1994) [Pubmed]
  42. Pharmacokinetics of baicalin in rats and its interactions with cyclosporin A, quinidine and SKF-525A: a microdialysis study. Tsai, P.L., Tsai, T.H. Planta Med. (2004) [Pubmed]
WikiGenes - Universities